Literature DB >> 18768519

Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.

Kimberly A Lowe1, Chirag Shah, Erin Wallace, Garnet Anderson, Pamela Paley, Martin McIntosh, M Robyn Andersen, Nathalie Scholler, Lindsay Bergan, Jason Thorpe, Nicole Urban, Charles W Drescher.   

Abstract

OBJECTIVE: To evaluate if serum levels of candidate ovarian cancer biomarkers vary with individual characteristics of healthy women who are likely candidates for an ovarian cancer screening program.
METHODS: We analyzed serum CA125, mesothelin, and HE4 levels in a sample of 155 healthy postmenopausal women at increased risk for developing ovarian cancer based on personal and family cancer history. Information on reproductive, family and medical histories, lifestyle factors, and anthropometry was collected by self-report. Twenty-two factors were examined using univariate and multiple linear regression models for the three biomarker levels.
RESULTS: In the multivariate models, CA125 levels were significantly higher in women who had used talcum powder (P = 0.02) and were lower in women who were parous (P = 0.05). Mesothelin levels were significantly higher in older women (P = 0.01) and lower in heavier women (P = 0.03). HE4 levels were higher in older women (P = 0.001) and in women who began menstruating at an older age (P = 0.03).
CONCLUSIONS: CA125, mesothelin, and HE4 levels in healthy, postmenopausal women at increased risk for ovarian cancer are significantly associated with a few ovarian cancer risk factors. Since the effects of these personal characteristics on these serum markers are not large, their incorporation in screening algorithms may be unnecessary. This is true especially if a longitudinal algorithm is used because the marker level at the previous screen reflects personal characteristics such as age, body mass index, and age of menarche. Understanding the influence of personal factors on levels of novel early detection markers in healthy, unaffected women may have clinical utility in interpreting biomarker levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768519      PMCID: PMC2632599          DOI: 10.1158/1055-9965.EPI-08-0150

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  26 in total

1.  Factors influencing serum CA125II levels in healthy postmenopausal women.

Authors:  D K Pauler; U Menon; M McIntosh; H L Symecko; S J Skates; I J Jacobs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-05       Impact factor: 4.254

2.  How valid are self-reported height and weight? A comparison between CATI self-report and clinic measurements using a large cohort study.

Authors:  Anne W Taylor; Eleonora Dal Grande; Tiffany K Gill; Catherine R Chittleborough; David H Wilson; Robert J Adams; Janet F Grant; Patrick Phillips; Sarah Appleton; Richard E Ruffin
Journal:  Aust N Z J Public Health       Date:  2006-06       Impact factor: 2.939

3.  Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas.

Authors:  M Schummer; W V Ng; R E Bumgarner; P S Nelson; B Schummer; D W Bednarski; L Hassell; R L Baldwin; B Y Karlan; L Hood
Journal:  Gene       Date:  1999-10-01       Impact factor: 3.688

Review 4.  Ovarian cancer: epidemiology, biology, and prognostic factors.

Authors:  C H Holschneider; J S Berek
Journal:  Semin Surg Oncol       Date:  2000 Jul-Aug

5.  Generating longitudinal screening algorithms using novel biomarkers for disease.

Authors:  Martin W McIntosh; Nicole Urban; Beth Karlan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-02       Impact factor: 4.254

6.  Bead-based ELISA for validation of ovarian cancer early detection markers.

Authors:  Nathalie Scholler; Meghan Crawford; Alicia Sato; Charles W Drescher; Kathy C O'Briant; Nancy Kiviat; Garnet L Anderson; Nicole Urban
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

7.  Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome.

Authors:  J M Riedinger; F Bonnetain; J P Basuyau; N Eche; H Larbre; I Dalifard; J Wafflart; G Ricolleau; M F Pichon
Journal:  Ann Oncol       Date:  2007-02-13       Impact factor: 32.976

8.  Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Authors:  Daniel G Rosen; Lin Wang; J Neeley Atkinson; Yinhua Yu; Karen H Lu; Eleftherios P Diamandis; Ingegerd Hellstrom; Samuel C Mok; Jinsong Liu; Robert C Bast
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

9.  Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.

Authors:  S J Skates; F J Xu; Y H Yu; K Sjövall; N Einhorn; Y Chang; R C Bast; R C Knapp
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

Review 10.  CA 125: the past and the future.

Authors:  R C Bast; F J Xu; Y H Yu; S Barnhill; Z Zhang; G B Mills
Journal:  Int J Biol Markers       Date:  1998 Oct-Dec       Impact factor: 3.248

View more
  37 in total

1.  Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Authors:  Richard G Moore; Michael Craig Miller; Elizabeth E Eklund; Karen H Lu; Robert C Bast; Geralyn Lambert-Messerlian
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

2.  Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Authors:  Mehmet Bayram; Isa Dongel; Ali Akbaş; Ismail Benli; Muhammed Emin Akkoyunlu; Nur Dilek Bakan
Journal:  Lung       Date:  2013-10-30       Impact factor: 2.584

3.  fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.

Authors:  Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Expert Opin Med Diagn       Date:  2011-05-01

4.  Potential role of HE4 in multimodal screening for epithelial ovarian cancer.

Authors:  Nicole Urban; Jason D Thorpe; Lindsay A Bergan; Robin M Forrest; Archana V Kampani; Nathalie Scholler; Kathy C O'Briant; Garnet L Anderson; Daniel W Cramer; Christine D Berg; Martin W McIntosh; Patricia Hartge; Charles W Drescher
Journal:  J Natl Cancer Inst       Date:  2011-09-14       Impact factor: 13.506

5.  Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.

Authors:  Michael K Felten; Khaled Khatab; Lars Knoll; Thomas Schettgen; Hendrik Müller-Berndorff; Thomas Kraus
Journal:  Int Arch Occup Environ Health       Date:  2013-02-20       Impact factor: 3.015

6.  DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.

Authors:  Sahar Houshdaran; Sarah Hawley; Chana Palmer; Mihaela Campan; Mari N Olsen; Aviva P Ventura; Beatrice S Knudsen; Charles W Drescher; Nicole D Urban; Patrick O Brown; Peter W Laird
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

7.  Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum.

Authors:  Daniel Gilbert Weber; Georg Johnen; Dirk Taeger; Anne Weber; Isabelle Mercedes Gross; Beate Pesch; Thomas Kraus; Thomas Brüning; Monika Gube
Journal:  Biomark Insights       Date:  2010-01-28

8.  The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.

Authors:  Charles W Drescher; J David Beatty; Robert Resta; M Robyn Andersen; Kate Watabayashi; Jason Thorpe; Sarah Hawley; Hannah Purkey; Jessica Chubak; Nancy Hanson; Diana S M Buist; Nicole Urban
Journal:  Cancer       Date:  2016-07-22       Impact factor: 6.860

9.  Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

Authors:  M Robyn Andersen; Barbara A Goff; Kimberly A Lowe; Nathalie Scholler; Lindsay Bergan; Charles W Drescher; Pamela Paley; Nicole Urban
Journal:  Gynecol Oncol       Date:  2009-11-28       Impact factor: 5.482

10.  Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.

Authors:  Nicole Urban; Jason Thorpe; Beth Y Karlan; Martin W McIntosh; Melanie R Palomares; Mary B Daly; Pamela Paley; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-09-07       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.